Capricor Therapeutics, Inc.
CAPR
$26.01
-$0.15-0.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 11.13M | 13.39M | 17.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 11.13M | 13.39M | 17.36M |
| Cost of Revenue | 92.92M | 84.45M | 75.88M | 67.33M | 57.78M |
| Gross Profit | -92.92M | -84.45M | -64.75M | -53.93M | -40.42M |
| SG&A Expenses | 27.02M | 23.69M | 21.94M | 19.47M | 16.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 119.93M | 108.14M | 97.81M | 86.80M | 74.64M |
| Operating Income | -119.93M | -108.14M | -86.68M | -73.41M | -57.28M |
| Income Before Tax | -114.59M | -105.04M | -81.99M | -69.97M | -55.06M |
| Income Tax Expenses | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K |
| Earnings from Continuing Operations | -114.59 | -105.04 | -81.99 | -69.98 | -55.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.59M | -105.04M | -81.99M | -69.98M | -55.06M |
| EBIT | -119.93M | -108.14M | -86.68M | -73.41M | -57.28M |
| EBITDA | -117.91M | -106.25M | -84.92M | -71.78M | -55.78M |
| EPS Basic | -2.31 | -2.26 | -1.80 | -1.64 | -1.42 |
| Normalized Basic EPS | -1.44 | -1.41 | -1.12 | -1.02 | -0.88 |
| EPS Diluted | -2.31 | -2.26 | -1.80 | -1.64 | -1.42 |
| Normalized Diluted EPS | -1.44 | -1.41 | -1.12 | -1.02 | -0.88 |
| Average Basic Shares Outstanding | 197.71M | 185.91M | 181.57M | 168.95M | 155.08M |
| Average Diluted Shares Outstanding | 197.71M | 185.91M | 181.57M | 168.95M | 155.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |